Hepatitis C Combination Therapy - Antibodies Neutralizing Peginterferon Alfa during Retreatment of

Antibodies Neutralizing Peginterferon Alfa during Retreatment of
New England Journal of Medicine - To the Editor: Peginterferons are widely used to treat chronic hepatitis C virus (HCV) infection, an important cause of liver cirrhosis and hepatocellular carcinoma. 1 , 2 , 3 , 4 We describe a patient who did not have a virologic response to

Hepatitis C Market: Plenty Of Potential, But Little Progress
Investors Business Daily - The month of March was not kind to a pair of companies racing to find a cure or vaccine for hepatitis C, the often fatal liver disease that's been called a global epidemic by the World Health Organization. On March 21, Valeant Pharmaceuticals ( VRX

MIGENIX to Present at BIO 2006
Genetic Engineering News - VANCOUVER , BC, and SAN DIEGO , CA, April 6 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has been selected to present at the BIO 2006 Business Forum which

Cuban Combined Therapy Against Chronic Hepatitis C
Ahora.cu - A Cuban combination therapy for the treatment of chronic Hepatitis C is to be put on the market by the Heber Biotec S.A. company in Latin America, Asia, Africa, the Middle East and Europe, where this firm has registered the Heberon Alfa R (human

Chinese Patients With Chronic Hepatitis B Respond Better To
Medical News Today - Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and Novartis (NYSE: NVS) today announced new data that demonstrate telbivudine, an investigational oral, once-daily nucleoside analogue, provided significantly greater antiviral and clinical efficacy in

Hepatitis Still a Frustrating Foe
Street.Com - Since March 14, three drugmakers, Human Genome Sciences ( HGSI :Nasdaq - news - research - Cramer's Take ), Idenix Pharmaceuticals ( IDIX :Nasdaq - news - research - Cramer's Take ) and Valeant Pharmaceuticals ( VRX :NYSE - news - research - Cramer's